That’s right, the company is not walking away from DMD, it just won’t be the lead programme. If they can seriously outperform the competition then they will be open to partnership. It’s worth going back to the matrix to understand the range of technologies, diseases and tissue targets that the company has in its sights. I’ve seen the matrix several times and have been looking at it as a progress chart, when in fact it is a statement of scalability - the company is definitely not a one hit wonder. The challenge seems to be which one rather than can we.
PYC Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)